To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Chronic Inflammatory Demyelinating Polyneuropathy

In brief

This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes an up to 4-week Screening Period, an up to 12-week Washout Period, a 12-week Randomized Treatment Period (Period 1), an up to 24-week Randomized Withdrawal Period (Period 2), an up to 52-week Long-term Extension (LTE) Period (optional), and Safety Follow-up 4 weeks after the last dose of study treatment. The total study duration will be up to approximately 109 weeks. Eligible participants will be assigned to one of four cohorts based upon their baseline CIDP treatment (Cohorts A and D - immunoglobulin \[Ig\] or plasma exchange \[PLEX\]; Cohort B - corticosteroids; Cohort C - naive or untreated in previous 3-24 months) and whether they meet diagnosis according to the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria (Cohorts A, B, and C) or clinical criteria only (Cohort D) at the time of screening.

Key facts

Study ID

NCT05581199

Run by

Immunovant Sciences GmbH

People needed

277

Starts

2022-12-15

Expected to finish

2027-01-01

Last updated by the study team

2024-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All Cohorts:
• Are >= 18 years at the Screening Visit.
• Have met clinical diagnostic criteria for typical CIDP, or one of the following CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP. Clinical criteria for typical CIDP and variants are as follows (either criterion must be met):
• Typical CIDP: All the following:
• Progressive or relapsing, symmetric, proximal, and distal muscle weakness of upper and lower limbs, and sensory involvement of at least two limbs (at any point in the disease course)
• Developing over at least 8 weeks
• Absent or reduced tendon reflexes in all limbs
• CIDP variants: One of the following, but otherwise as in typical CIDP (tendon reflexes may be normal in unaffected limbs):
• Multifocal CIDP: documented sensory loss and muscle weakness in a multifocal pattern, usually asymmetric, upper limb predominant
• Focal CIDP: sensory loss and muscle weakness in only one limb
• Motor CIDP: motor symptoms and signs without sensory involvement
• Cohorts A and B:
• Have electrodiagnostic test results supporting the diagnosis of CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP; for Cohorts A and B, either criterion must be met:
• Motor nerve conduction criteria strongly supportive of demyelination.
• Motor nerve conduction criteria weakly supportive of demyelination and 2 or more of the following additional diagnostic criteria:
• Objective improvement to an empiric trial of therapy with immunoglobulin treatment, plasma exchange (PLEX), or corticosteroids.
• Diagnostic imaging by ultrasound or magnetic resonance imaging (MRI) supporting the diagnosis of CIDP by demonstrating nerve enlargement.
• Cerebrospinal fluid (CSF) demonstrating albuminocytologic dissociation (i.e., elevated CSF protein level [defined as > 70 milligrams per deciliter {mg/dL} or > 10 mg/dL greater than years of age for those aged 60 years and over] with normal CSF white blood cell [WBC] level).
• Nerve biopsy demonstrating features supporting the diagnosis of CIDP, such as edema, demyelination, and/or onion bulb formation.
• Cohort C only:
• Have a diagnosis of CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP based on clinical criteria and motor nerve conduction criteria strongly supportive of demyelination (i.e., motor nerve conduction criteria weakly supportive of demyelination is insufficient diagnostic evidence for admission to Cohort C).
• Cohort D only:
• Have met only clinical diagnostic criteria for typical CIDP, or one of the following CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP. Either inclusion criterion 2(a) or 2(b) must be met.
• Additional inclusion criteria are defined in the protocol.

You may not qualify if…

• All Cohorts:
• Have current or prior history of immunoglobulin M (IgM) paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies.
• Have Distal CIDP, Sensory CIDP or are suspected of having a diagnosis of auto-immune nodopathy in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP.
• Have polyneuropathy of causes other than CIDP including but not limited to:
• Multifocal motor neuropathy
• Hereditary demyelinating neuropathy
• Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS)
• Lumbosacral radiculoplexus neuropathy
• Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies
• Drug- or toxin-induced
• Have diabetes mellitus (DM) and meets any of the following criteria:
• Does not meet inclusion criteria 2(a) and 3(a).
• In the opinion of the Investigator, there is evidence of poorly controlled DM preceding the diagnosis of CIDP.
• In the opinion of the Investigator, there is evidence of poorly controlled DM at screening.
• Have a history of myelopathy or evidence of central demyelination.
• Are receiving chronic oral corticosteroids monotherapy at a dose > 40 mg/day prednisolone/prednisone or its equivalent at the Screening Visit.
• Are receiving chronic oral corticosteroid at a dose > 10 mg/day prednisolone/prednisone or equivalent in combination with immunoglobulin therapy or PLEX at the Screening Visit.
• Additional exclusion criteria are defined in the protocol.

Where it is running

• Site Number - 6345 — Athens, Attica, Greece
• Site Number - 6341 — Pátrai, Achaïa, Greece
• Site Number - 1603 — Scottsdale, Arizona, United States
• Site Number - 1618 — Carlsbad, California, United States
• Site Number - 1634 — Los Angeles, California, United States
• Site Number - 1619 — Orange, California, United States
• Site Number - 1608 — San Francisco, California, United States
• Site Number - 1625 — Aurora, Colorado, United States
• Site Number - 1636 — Fort Collins, Colorado, United States
• Site Number - 1621 — New Haven, Connecticut, United States
• Site Number - 1630 — Washington D.C., District of Columbia, United States
• Site Number - 1600 — Boca Raton, Florida, United States
• Site Number - 1609 — Jacksonville, Florida, United States
• Site Number - 1631 — Orlando, Florida, United States
• Site Number - 1629 — Orlando, Florida, United States
• Site Number - 1617 — Ormond Beach, Florida, United States
• Site Number - 1620 — Port Charlotte, Florida, United States
• Site Number - 1633 — Rockledge, Florida, United States
• Site Number - 1604 — St. Petersburg, Florida, United States
• Site Number - 1607 — O'Fallon, Illinois, United States
• Site Number - 1602 — Kansas City, Kansas, United States
• Site Number - 1611 — Nicholasville, Kentucky, United States
• Site Number - 1622 — Brooklyn, New York, United States
• Site Number - 1605 — New York, New York, United States
• Site Number - 6344 — Athens, Attica, Greece

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.